CRSP Aiming for $44-49 First Target- Currently in shares.I am looking at my Algos, and Oscillators timed up with support and resistance lines showing a pretty clear breakout of the beatdown that CRSP has been getting. Cheers!
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−55.19 MXN
−2.61 B MXN
6.30 B MXN
81.70 M
About CRISPR Therapeutics AG
Sector
Industry
CEO
Samarth Kulkarni
Website
Headquarters
Zug
Founded
2013
ISIN
CH0334081137
FIGI
BBG00W2QZYG9
CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.
$CRSP: A BioTech to add to the watchlist! 95% UpsideNASDAQ:CRSP
Not a High Five Setup...yet
-H5 Indicator is GREEN
-Filling Volume Profile GAP and setting up at a new Volume Profile Shelf
-Need Wr% to push up above -20 and form Williams Consolidation Box
-Need to breakout of Symmetrical Triangle at $56ish
If we get that it will be a H5 Trade and
Looking for the next Amazon or Tesla to invest at the Start?CRISPR Therapeutics - revenue projection = Massive
I am accumulating shares. you may want to start looking into CrSp.Let's calculate the revenue potential for CRISPR Therapeutics based on their approved therapy and pipeline:
THERAPY 1: BEING ROLLED OUT AND APPROVED IN THE USA AND EUROPE
Casgevy (
Cound this be ? and yet maybe is will.....CRISPR Therapeutics - the next Trillion Dollar Company.
November 14, 2024
Investing ins SpaceX before it goes Public.... This is good advice !!! Space is the new War Economy, I mead the defense machine needs a new business line, and space is more profitable than any war economy X 50 - war economy
4 hour bullish divergence It was pointed out to me earlier that the last time I posted was back in May so I thought I’d pull my finger out and share this one.
The company has developed a cure for sickle cell disease, by gene editing, this disease is seriously debilitating and affects millions of people of African descent, t
CRSPR 72824I am looking to start a dca campaign here. I see value at the 50 level. I have no clue where its going short/mid term. Over the long term i see it continuing its upward march. Looks very bullish over the long term.
CRSP: This company is losing moneyNot only are they losing money they took out a bunch of high interest debt. They're going to start hemorrhaging. However long it takes, they're going to the single digits in stock price.
CRSP | Time to Start Accumulating | LONGCRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. T
CRSPBought today, got a nice move.
Published earlier this idea on X
Getting an extension, I am trading this impulse up only
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of CRSP/N is 887.50 MXN — it has decreased by −6.58% in the past 24 hours. Watch CRISPR THERAPEUTICS AG stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BIVA exchange CRISPR THERAPEUTICS AG stocks are traded under the ticker CRSP/N.
CRSP/N stock has fallen by −6.39% compared to the previous week, the month change is a −6.39% fall, over the last year CRISPR THERAPEUTICS AG has showed a −22.18% decrease.
We've gathered analysts' opinions on CRISPR THERAPEUTICS AG future price: according to them, CRSP/N price has a max estimate of 4,045.54 MXN and a min estimate of 609.88 MXN. Watch CRSP/N chart and read a more detailed CRISPR THERAPEUTICS AG stock forecast: see what analysts think of CRISPR THERAPEUTICS AG and suggest that you do with its stocks.
CRSP/N stock is 7.04% volatile and has beta coefficient of 1.75. Track CRISPR THERAPEUTICS AG stock price on the chart and check out the list of the most volatile stocks — is CRISPR THERAPEUTICS AG there?
Today CRISPR THERAPEUTICS AG has the market capitalization of 70.52 B, it has decreased by −1.85% over the last week.
Yes, you can track CRISPR THERAPEUTICS AG financials in yearly and quarterly reports right on TradingView.
CRISPR THERAPEUTICS AG is going to release the next earnings report on Feb 18, 2025. Keep track of upcoming events with our Earnings Calendar.
CRSP/N earnings for the last quarter are −19.90 MXN per share, whereas the estimation was −27.28 MXN resulting in a 27.06% surprise. The estimated earnings for the next quarter are −24.60 MXN per share. See more details about CRISPR THERAPEUTICS AG earnings.
CRISPR THERAPEUTICS AG revenue for the last quarter amounts to 11.86 M MXN, despite the estimated figure of 129.39 M MXN. In the next quarter, revenue is expected to reach 154.00 M MXN.
CRSP/N net income for the last quarter is −1.69 B MXN, while the quarter before that showed −2.32 B MXN of net income which accounts for 26.96% change. Track more CRISPR THERAPEUTICS AG financial stats to get the full picture.
No, CRSP/N doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has 407.00 employees. See our rating of the largest employees — is CRISPR THERAPEUTICS AG on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CRISPR THERAPEUTICS AG EBITDA is −6.17 B MXN, and current EBITDA margin is −54.61%. See more stats in CRISPR THERAPEUTICS AG financial statements.
Like other stocks, CRSP/N shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CRISPR THERAPEUTICS AG stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CRISPR THERAPEUTICS AG technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CRISPR THERAPEUTICS AG stock shows the sell signal. See more of CRISPR THERAPEUTICS AG technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.